Literature DB >> 17983760

Multifocal T4 non-small cell lung cancer: a subset with improved prognosis.

Delphine Trousse1, Xavier Benoît D'Journo, Jean-Philippe Avaro, Christophe Doddoli, Roger Giudicelli, Pierre Antoine Fuentes, Pascal Alexandre Thomas.   

Abstract

OBJECTIVE: T4-disease for non-small cell lung cancer (NSCLC) includes different conditions: mediastinal invasion, neoplastic pleural cytology, and multifocal disease in the same lobe; regarding the last category, no strict criteria allow to differentiate satellite nodules from synchronous multiple primary tumours.
METHODS: Retrospective study of 56 patients who underwent a complete resection from 1985 to 2006 of a NSCLC graded pT4N0 due to multifocal disease. A small nodule (<1cm) closed to the primary tumour, in a same pulmonary segment with an identical histology was considered as a satellite nodule (pT4sn). Multiple tumours, sized more than 1cm, with an identical histology, located in the same lobe but in different segment were considered as synchronous cancers (pT4sc).
RESULTS: There were 44 males and 12 females: 35 patients were graded T4sn and 21 patients T4sc. The median age was 62.5 years. The two groups were similar for sex, age, tobacco consumption, ASA score, NYHA, Charlson's index, spirometric parameters, cardiovascular comorbidity and history of previous extra-thoracic malignancies. All had a complete anatomic resection with mediastinal lymphadenectomy. Thirty-day mortality rate was 3.6%. Overall 5-year and 10-year survival rates were 48.2% and 29.9%, respectively. There was a non-significant trend for a worse survival in T4sn group patients when compared to that of T4sc group patients: 42.9% vs 52.3% at 5 years, and 25% vs 34.9% at 10 years (p=0.62).
CONCLUSIONS: Multifocal T4 stage IIIB disease is a heterogeneous category where overall prognosis is far better than those of other T4 subgroups. Survival rates associated with pT4sn and pT4sc look roughly similar because of the small size of the subgroups usually submitted to comparison in most series. In the present experience, respective survival figures diverge, suggesting different biological behaviours.

Entities:  

Mesh:

Year:  2007        PMID: 17983760     DOI: 10.1016/j.ejcts.2007.09.032

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

1.  Multifocal lung cancers--clonality vs field cancerization and does it matter?

Authors:  Adi F Gazdar; John D Minna
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

2.  Significance of nonmucinous lepidic component with mild nuclear atypia in the discrimination of multiple primary lung cancers from intrapulmonary metastases.

Authors:  Wei Sun; Yu Liu; Xiang-Yang Liu; Dong-Mei Lin; Ning Lv
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

3.  Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment.

Authors:  Nika Guberina; Christoph Pöttgen; Martin Schuler; Maja Guberina; Georgios Stamatis; Till Plönes; Martin Metzenmacher; Dirk Theegarten; Thomas Gauler; Kaid Darwiche; Clemens Aigner; Wilfried E E Eberhardt; Martin Stuschke
Journal:  Radiat Oncol       Date:  2022-07-16       Impact factor: 4.309

4.  Comprehensive genomic profiling aids in understanding the lesion origins of a patient with six synchronous invasive lung adenocarcinomas: a case study.

Authors:  Yang Song; Ziqi Jia; Pancheng Wu; Weiwei Wang; Qiuxiang Ou; Hua Bao; Man Yu; Xue Wu; Peng Liu; Naixin Liang; Shuyang Zhang; Shanqing Li
Journal:  BMC Pulm Med       Date:  2020-04-03       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.